Literature DB >> 9356351

p53/E1b58kDa complex regulates adenovirus replication.

P J Ridgway1, A R Hall, C J Myers, A W Braithwaite.   

Abstract

We have explored a role for the adenovirus (Ad5) E1b58kDa/p53 protein complex in adenovirus replication. This was done by using virus mutants containing different defects in the E1b58kDa gene and cell lines that express either a wild-type p53 protein or a mutant p53 protein. We find that infection of wild-type p53-containing cells with wild-type Ad5 causes a shutoff of p53 and alpha-actin protein synthesis by distinct mechanisms, but neither occurs in mutant p53 cells. Our data also indicate that the shutoff is dependent on formation of the p53/E1b complex and may also involve another virus protein, E4ORF6. Following from these observations we asked whether failure to form the complex resulted in impaired adenovirus replication. Our experiments showed that neither wild-type Ad5 nor the E1b mutant dl338 could replicate in cells expressing a mutant p53 protein, but that wild-type adenovirus replicated well in wild-type p53-expressing cells. Collectively, our data suggest that the interaction between p53 and the E1b58kDa protein is necessary for efficient adenovirus replication. This is the first time such a direct link between the complex and virus replication has been demonstrated. These data raise serious questions about the usefulness of E1b-defective viruses in tumor therapy. Copyright 1997 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356351     DOI: 10.1006/viro.1997.8782

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication.

Authors:  J N Harada; A J Berk
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 2.  Participation of recombination proteins in rescue of arrested replication forks in UV-irradiated Escherichia coli need not involve recombination.

Authors:  J Courcelle; P C Hanawalt
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

Review 3.  Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Authors:  B R Dix; S J Edwards; A W Braithwaite
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

Authors:  Sara J Edwards; Brett R Dix; Colleen J Myers; Deirdre Dobson-Le; Lily Huschtscha; Merilyn Hibma; Janice Royds; Antony W Braithwaite
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Adenovirus E1B 55-kilodalton protein is required for both regulation of mRNA export and efficient entry into the late phase of infection in normal human fibroblasts.

Authors:  Ramon Gonzalez; Wenying Huang; Renee Finnen; Courtney Bragg; S J Flint
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 6.  Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation.

Authors:  Andrew N Blackford; Roger J A Grand
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

7.  p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection.

Authors:  F D Goodrum; D A Ornelles
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

8.  Normal human cell proteins that interact with the adenovirus type 5 E1B 55kDa protein.

Authors:  George Hung; S J Flint
Journal:  Virology       Date:  2017-01-27       Impact factor: 3.616

9.  The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status.

Authors:  A S Turnell; R J Grand; P H Gallimore
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  The p53 protein does not facilitate adenovirus type 5 replication in normal human cells.

Authors:  Jasdave S Chahal; S J Flint
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.